PHIM Responsive Header

Year: 2025

  • NHSRC Protocol Forms.

    NHSRC Protocol Forms.

    Research Division: NHSRC Forms Guide
    ESSENTIAL GUIDANCE

    NHSRC Protocol Forms: Streamlining Ethical Review

    The Research Division has updated its official National Health Sciences Research Committee (NHSRC) forms. Below, find the documents required for researchers to download, submit, and manage protocols, followed by the internal forms used for NHSRC oversight.

    1. Researcher Action Forms (Downloadable)

    These forms are mandatory for researchers to initiate, modify, renew, or close a study protocol. Click to download the official template.

    FORM 101  

    Initial Submission

    Application to Conduct Health Research

    This is the mandatory initial application form required for all researchers intending to conduct human health research under the NHSRC’s jurisdiction. It serves as the comprehensive formal submission that officially initiates the ethical review process by providing all necessary preliminary data. Researchers must include essential protocol information, institutional endorsements, and a complete checklist of supporting documents such as the full proposal, informed consent forms, and investigator CVs.

    Download Form →

    Checklist Form

    Pre-Submission

    Protocol Submission Checklist

    This essential document must be completed by the Principal Investigator prior to submitting the study proposal to the NHSRC. It serves as a comprehensive self-audit tool, ensuring that all mandatory components—including the main proposal, Form 101, informed consent documents, CVs, evidence of funding, and payment—are included. Submitting a proposal without completing this checklist or without all required elements will lead to automatic rejection or significant delays in the review process.

    Download Form →

    FORM 10-01  

    Post-Approval

    Request for Amendment / Modification

    This form is strictly required when a Principal Investigator needs to request any changes to a study protocol that has already received NHSRC approval. Researchers must clearly detail the proposed modifications, providing the specific reasons necessitating the amendment to the ongoing project. Any changes cannot be implemented until official NHSRC approval for the amendment has been formally granted and documented.

    Download Form →

    FORM 11-01

    Annual Oversight

    Application for Continuing Review

    The Continuing Review form is mandatory for all ongoing research protocols to ensure continued ethical compliance and participant welfare past the initial approval period. This process mandates the Principal Investigator to provide a detailed progress report and certify the ongoing ethical conduct of the study. Failure to submit this application in time can result in the suspension or termination of the research.

    Download Form →

    FORM 14-01   

    Closing Study

    Protocol Termination Notification

    This form must be submitted to the NHSRC to formally notify the committee of the conclusion or early termination of an approved research protocol. It requires key administrative details, including the protocol number and the final number of participants enrolled, as well as a concise summary of the study’s results at the time of termination. This ensures proper closure of the research file and provides final accountability for human subjects.

    Download Form →

    FORM 15-01

    Final Reporting

    Study Report Submission Form

    This form is used by the Principal Investigator to submit comprehensive information regarding the completed research project. It collects critical details about the study, the number of subjects treated, and dosage information. Most importantly, it requires a detailed summary of the final results and findings. This submission is vital for the NHSRC’s record-keeping and for demonstrating the research outcomes and accountability.

    Download Form →

    SAE Form

    Safety Alert

    Serious Adverse Event Reporting Form

    This specialized form is designed for the urgent, mandatory reporting of any Serious Adverse Event (SAE) that occurs during a study. It collects critical, time-sensitive information, including causality assessment related to the study intervention, the outcome for the participant, and the severity of the event. Prompt reporting is essential for participant safety and regulatory compliance throughout the study’s duration.

    Download Form →

    MTA Form

    Material/Sample

    Material Transfer Agreement Form

    The Material Transfer Agreement (MTA) Form is mandatory for research protocols involving the transfer or export of materials, such as biological samples, to institutions outside the collection site. It requires detailed documentation of the intention, scientific justification for the transfer, duration of storage, and strict prohibitions against the sale of samples collected in Malawi without prior approval.

    Download Form →

    2. NHSRC Internal Oversight Forms (Descriptive Only)

    These documents are used internally by the NHSRC, its reviewers, and its monitors. The summaries below outline the standards and compliance metrics researchers should be aware of, but the forms themselves are not available for public download.

    FORM 701

    Reviewer Use Only

    Protocol Assessment Form

    This is the crucial internal instrument used by designated NHSRC reviewers to systematically evaluate research protocols. It provides a structured checklist for assessing scientific and ethical integrity, focusing on clarity of objectives, methodological soundness, fairness of risk-benefit assessments, and ethical considerations like informed consent and confidentiality provisions. This form standardizes the review process and is the basis for the committee’s decision (e.g., approval, minor/major modifications, or rejection). Researchers should ensure their submissions address all these core areas comprehensively.

    Internal Document →

    FORM 19-01

    Site Monitoring

    Inspection Visit Form

    This form is utilized by NHSRC representatives or appointed monitors when conducting an on-site visit to a research location. It documents the purpose and outcomes of the inspection, covering administrative details, study status, and protocol compliance. The form serves as a structured report to the committee, ensuring that research sites adhere to the approved protocol, Good Clinical Practice (GCP) guidelines, and regulatory requirements throughout the study’s lifespan. Researchers should expect this level of oversight during the life of the study.

    Internal Document →

    Inspection Checklist

    Site Monitoring Tool

    Site Inspection Checklist

    This checklist is used in conjunction with the Inspection Visit Form (19-01) to systematically audit specific elements of a research site’s operation. Areas covered include: informed consent processes, drug accountability, data management, Quality Assurance (QA) systems, staff training records (GCP/Ethics), and appropriate waste disposal procedures. It ensures a standardized, thorough assessment of compliance across all participating sites. Knowing the categories on this checklist can help investigators proactively prepare for monitoring visits.

    Internal Document →

    FORM 02-01

    Ethical Compliance

    Confidentiality Agreement Form

    This is a foundational ethical requirement for all NHSRC members and external visitors attending committee meetings. The individual formally affirms their commitment to holding all confidential, proprietary, or sensitive protocol and participant information in the strictest confidence, except where disclosure is legally mandated. This agreement protects the privacy of research protocols and data during the ethical review process.

    Internal Document →

    FORM 20-01

    Ethical Compliance

    Conflict of Interest Form

    This document is completed by NHSRC members and staff to outline and manage any actual or potential conflicts of interest. It enforces the policy that no member may participate in the review or approval of an activity in which that member has a conflicting interest except to provide information as requested by the NHSRC. This mechanism is crucial for maintaining the impartiality and integrity of the review process.

    Internal Document →

    Need further Assistance?

    The NHSRC is dedicated to upholding the highest standards of ethics and scientific rigor. For any inquiries regarding protocol submission, review status, or compliance, please reach out to our team.

    Promoting Scientific and Ethical Conduct of Health Research in Malawi

    Reach out to:

    • Dr M. Joshua (Chairperson)
    • Dr F. Namboya (Vice-Chairperson)
    • Chikondi Chimbatata

    Registered with the USA Office for Human Research Protections (OHRP) as an International IRB

    IRB Number: IRB0000****05

    FWA Number: FWA0000****76

    Email: research@health.gov.mw

  • IDSR Epidemiological Bulletin – Week 46.

    IDSR Epidemiological Bulletin – Week 46.

    Malawi IDSR Infographic (Week 46, 2025)

    Editorial Team

    Dr. Matthews Kagoli Mrs. Mtisunge Yelewa Mr. Austin Zgambo Mr. Sikhona Chipeta Mr. James Jere Mr. Noel Khunga

    Weekly IDSR Bulletin

    Epidemiological Week 46 (10-16 November, 2025)

    Published By

    Moses Nyambalo Phiri

    Public Health Institute of Malawi

    National Surveillance Performance

    The Integrated Disease Surveillance and Response (IDSR) system continues to perform strongly. In Week 46, reporting completeness reached 94.8%. However, Central Hospitals significantly underperformed at 50%, highlighting a critical need for data integration support at tertiary facilities.

    Reporting Completeness
    94.8%
    +0.4% vs Week 45
    Reporting Timeliness
    91.9%
    -2.4% vs Week 45
    Performance Analysis The Central West zone achieved near-perfect scores (99.4% completeness), while the North Zone maintained high standards (98.0%). The drop in timeliness suggests potential logistical or connectivity challenges in specific districts that need addressing.

    Priority Disease Alerts

    Malaria remains the highest burden (20,796 cases, 16 deaths). Notably, Rabies alerts saw a significant rise to 11 suspected cases this week.

    Alert Insights Diarrhoea with blood cases slightly decreased to 1,077 but remain high. SARI cases increased to 65 with 4 deaths, reinforcing the need for respiratory surveillance. Meningitis cases also rose slightly to 7.

    Outbreak Spotlight: Mpox

    Surveillance remains active with 3 new confirmed cases and 40 suspected alerts in Week 46. The cumulative confirmed total is now 139.

    Epidemic Curve

    Trend Analysis While the major wave has subsided, the occurrence of 3 new cases indicates persistent low-level transmission. Continued vigilance and contact tracing are essential to prevent a resurgence.

    Demographic Impact

    Recovery Status 131 cases (94.2%) have successfully recovered. Currently, active management involves isolating confirmed cases to break chains of transmission.

    Outbreak Spotlight: Measles

    Measles outbreaks are evolving. While Balaka remains the epicenter, Machinga and Nsanje have seen increases in case numbers (24 and 22 respectively). Total cases: 126.

    Geographic Clusters

    Hotspots The rise in cases in Nsanje (22) and Machinga (24) signals widening local transmission in the Southern region, requiring intensified vaccination campaigns.

    Vaccination Status

    Data Gap The majority of cases still have unknown vaccination status. Strengthening routine immunization data capture is critical for outbreak analysis.

    Event-Based Surveillance (EBS)

    39 signals were reported this week. The risk profile has diversified, now identifying events classified as Very High Risk (2) and Very Low Risk (1).

    1

    Detection

    39 signals reported (Decrease from 49 in Wk 45).

    2

    Verification

    9 signals (23.1%) verified as genuine public health events.

    3

    Response

    2 Very High Risk events identified requiring urgent intervention.

    Risk Profile Breakdown

    Signal Triage 30 signals (77%) remain unclassified. The presence of “Very High” risk signals emphasizes the importance of the verification process.
    Download Official Bulletin (PDF)

    © 2025 Public Health Institute of Malawi. All Rights Reserved.

  • IDSR Epidemiological Bulletin – Week 45.

    IDSR Epidemiological Bulletin – Week 45.

    Malawi IDSR Infographic (Week 45, 2025)

    Editorial Team

    Dr. Matthews Kagoli Mrs. Mtisunge Yelewa Mr. Austin Zgambo Mr. Sikhona Chipeta Mr. James Jere Mr. Noel Khunga

    Weekly IDSR Bulletin

    Epidemiological Week 45 (November, 2025)

    Published By

    Moses Nyambalo Phiri

    Public Health Institute of Malawi

    National Surveillance Performance

    The Integrated Disease Surveillance and Response (IDSR) system serves as the backbone of Malawi’s public health security. In Week 45, the system maintained high reporting standards, ensuring timely data for rapid decision-making.

    Reporting Completeness
    94.4%
    -3.3% vs Week 44
    Reporting Timeliness
    94.3%
    +4.8% vs Week 44
    Performance Analysis The North Zone set the benchmark with 98.7% reporting rates. While the national average remains strong, targeted interventions are required for Central Hospitals, which reported at 75%, slightly below the 80% national target.

    Priority Disease Alerts

    Beyond Malaria (20,110 cases), the system actively tracked several critical conditions. Immediate investigations were launched for all alerts to prevent community spread.

    Alert Insights Bloody Diarrhoea triggered the highest volume of alerts (1,122 cases), necessitating water quality assessments. SARI (Severe Acute Respiratory Infections) showed a concerning mortality rate (6 deaths among 44 cases), highlighting the severity of current respiratory pathogens.

    Outbreak Spotlight: Mpox

    Containment efforts are showing success. Zero new confirmed cases were reported this week, though surveillance remains heightened with 25 suspected alerts investigated.

    Epidemic Curve

    Trend Analysis Transmission has significantly slowed following the peak in August/September. The flatlining curve in November indicates effective containment strategies.

    Demographic Impact

    Risk Groups The outbreak has disproportionately affected economically active groups: Business persons (25%), Students (22%), and Miners (21%).

    Outbreak Spotlight: Measles

    Active response continues for localized measles clusters. A total of 117 cases have been managed since August, with vaccination campaigns intensified in affected districts.

    Geographic Clusters

    Hotspots Balaka District accounts for >50% of all cases (62 cases), identifying it as the primary priority area for supplementary immunization activities.

    Vaccination Status

    Data Gap 75% of cases have an unknown vaccination history. This data gap is a critical challenge for verifying vaccine efficacy vs. coverage failure.

    Event-Based Surveillance (EBS)

    Community engagement has surged, with reported signals tripling from the previous week (14 to 49). This demonstrates improved sensitivity at the community level.

    1

    Detection

    49 signals reported by community members and health workers.

    2

    Verification

    11 signals (22%) verified as genuine public health events; 38 pending or discarded.

    3

    Response

    3 High Risk events triggered immediate RRT deployment. 6 Moderate, 2 Low.

    Risk Profile Breakdown

    Signal Triage The high number of “Unclassified” signals (78%) suggests a need for faster initial verification protocols to clear the backlog.
    Download Official Bulletin (PDF)

    © 2025 Public Health Institute of Malawi. All Rights Reserved.